Synthesis of 1-(3-Chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione

By Katherine Brimblecombe, PhD and Stephanie Cragg, PhD
View Published Protocol

Output Details

Description
1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione (8) is a potent and highly selective Ca(V)1.3 L-type calcium channel antagonist. This protocol is an adaption of Kang et al. 2012 's method of the synthesis of this chemical.
Identifier (DOI)
10.1101/2020.07.03.186411
Tags
  • Calcium
  • Drug development
  • Other
Team
Team Cragg
Program
Collaborative Research Network
Theme
Circuitry and Brain-Body Interactions

Meet the Authors

Related Research

Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s

This data show that LTCC function in DA axons, and isradipine effect, are locally governed and suggest they vary in a manner that in turn might impact on, or reflect, the cellular stress that leads to parkinsonian degeneration.

View Article

Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons

Cholinergic neurons (CNs) in the pedunculopontine nucleus (PPN) are lost in the course of Parkinson’s disease. PPN CNs have a distinctive physiological phenotype that shares only some of the features of other selectively vulnerable neurons in PD.

View Article

Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s

This data show that LTCC function in DA axons, and isradipine effect, are locally governed and suggest they vary in a manner that in turn might impact on, or reflect, the cellular stress that leads to parkinsonian degeneration.

View Article
View More Outputs